Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease -March 28, 2024 at 04:02 pm EDT

Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia ...

Related Keywords

Roland Chen ,Bristol Myers Squibb ,Facebook ,Twitter ,Exchange Commission ,Clinical Trial Program ,Youtube ,Instagram ,Linkedin ,Bristol Myers ,Disease Activity Index ,Simple Endoscopic Score ,Myers Squibb ,Pioneering Paths Forward ,Transform Patient ,Multifocal Leukoencephalopathy ,Atrioventricular Conduction Delays ,Blood Pressure ,Reversible Encephalopathy Syndrome ,Immune Modulating Drugs ,Multiple Sclerosis ,Disability After Stopping ,Common Adverse Reactions ,Specific Populations ,Hepatic Impairment ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,